0
0

Chapter 20. Clinical Psychopharmacology and Cognitive Remediation

Carol A. Tamminga, M.D.; Alan S. Bellack, Ph.D.; Stephen R. Marder, M.D.; Wayne S. Fenton, M.D.
DOI: 10.1176/appi.books.9781585622986.254299

Sections

Excerpt

Schizophrenia is a chronic psychotic illness. Symptoms have their onset in early adult years and last a lifetime, exacting a huge burden of human suffering and posing complex—and still unsolved—treatment questions. Psychotic behavior has been evident from the dawn of human history, but schizophrenia was not conceptualized as an illness until the mid-1800s, and it was not until the 1950s that even palliative treatments were available (Davis 1969). Since the 1950s, when the antipsychotic activity of chlorpromazine was discovered, two generations of antipsychotic drugs have been developed and considerable additional experimentation carried out with complementary treatment approaches (Geyer and Heinssen 2005). The prevailing orientation to pharmacotherapy in schizophrenia, until now, has been to prescribe a single drug directed toward a comprehensive treatment of the illness, like prescribing insulin to treat diabetes. The orientation has not been optimally successful, yet it has driven drug discovery until now.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
Table 20–1. Second-generation antipsychotics
Table Reference Number
Table 20–2. Involuntary movement scale

References

Akil M, Kolachana BS, Rothmond DA, et al: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23:2008–2013, 2003
[PubMed]
 
Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696, 1999
[PubMed]
 
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596–601, 2004
 
Andreasen N, Paradiso S, O'Leary D: "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 24:203–218, 1998
[PubMed]
 
Arato M, O'Connor R, Meltzer HY, et al: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17:207–215, 2002
[PubMed]
 
Arnsten AFT: Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174:25–31, 2004
[PubMed]
 
Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233–246, 1997
[PubMed]
 
Barch DM, Sheline YI, Csernansky JG, et al: Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biol Psychiatry 53:376–384, 2003
[PubMed]
 
Bell MD, Conway GT, Bryson G, et al: Patterns of object relations and reality testing deficits in schizophrenia: clusters and their symptom and personality correlates. J Clin Psychol 57:1353–1367, 2001
[PubMed]
 
Bellack AS: Skills training for people with severe mental illness. Psychiatr Rehabil J 27:375–391, 2004
[PubMed]
 
Bellack AS, Blanchard JJ, Murphy P, et al: Generalization effects of training on the Wisconsin Card Sorting Test for schizophrenia patients. Schizophr Res 19:189–194, 1996
[PubMed]
 
Bellack AS, Gold JM, Buchanan RW: Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull 25:257–274, 1999
[PubMed]
 
Bellack AS, Weinhardt LS, Gold JM, et al: Generalization of training effects in schizophrenia. Schizophr Res 48:255–262, 2001
[PubMed]
 
Bettinger TL, Mendelson SC, Dorson PG, et al: Olanzapine-induced glucose dysregulation. Ann Pharmacother 34:865–867, 2000
[PubMed]
 
Bilder RM, Lipschutz-Broch L, Reiter G, et al: Neuropsychological deficits in the early course of first episode schizophrenia. Schizophr Res 5:198–199, 1991
[PubMed]
 
Boehm G, Racoosin JA, Laughren TP, et al: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement. Diabetes Care 27:2088–2089, 2004
[PubMed]
 
Bond GR, Drake R, Mueser KT, et al: An update on supported employment for people with severe mental illness. Psychiatr Serv 48:335–346, 1997
[PubMed]
 
Braff DL: Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 19:233–259, 1993
[PubMed]
 
Brewer WJ, Francey SM, Wood SJ, et al: Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162:71–78, 2005
[PubMed]
 
Brickman AM, Buchsbaum MS, Bloom R, et al: Neuropsychological functioning in first-break, never-medicated adolescents with psychosis. J Nerv Men Dis 192:615–622, 2004
[PubMed]
 
Bruder GE, Wexler BE, Sage MM, et al: Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res 68:137–147, 2004
[PubMed]
 
Burstein ES, Ma JN, Wong S, et al: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278–1287, 2005
[PubMed]
 
Cannon TD, Huttunen MO, Lonnqvist J, et al: The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 67:369–382, 2000
[PubMed]
 
Carlsson A, Lindquist L: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–145, 1963
[PubMed]
 
Censits DM, Ragland JD, Gur RC, et al: Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res 24:289–298, 1997
[PubMed]
 
Cornblatt BA, Erlenmeyer-Kimling L: Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnorm Psychol 94:470–486, 1985
[PubMed]
 
Coward DM: General pharmacology of clozapine. Br J Psychiatry Suppl (May):5–11, 1992
 
Daniel DG, Zimbroff DL, Potkin SG, et al: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491–505, 1999
[PubMed]
 
Daniel DG, Potkin SG, Reeves KR, et al: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 155:128–134, 2001
[PubMed]
 
Davies MA, Compton-Toth BA, Hufeisen SJ, et al: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacology 178:451–460, 2005
[PubMed]
 
Davis JM: Review of antipsychotic drug literature, in Diagnosis and Drug Treatment of Psychiatric Disorders. Edited by Klein DF, Davis JM. Baltimore, MD, Williams & Wilkins, 1969, pp 52–138
 
Delay J, Deniker P: Trente-huit cas de psychoses traitees par la cure prolongee et continue de 4500 RP [Thirty-eight cases of psychosis treated by chronic treatment with 4500 RP], in Congres de Medecins Alienistes et Neurologistes de France. Edited by Ossa PC. Paris, Masson, 1952, pp 497–502
 
Dickinson D, Iannone VN, Wilk CM, et al: General and specific cognitive deficits in schizophrenia. Biol Psychiatry 55:826–833, 2004
[PubMed]
 
Eckman TA, Wirshing WC, Marder SR, et al: Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 149:1549–1555, 1992
[PubMed]
 
Egan MF, Goldberg TE, Kolachana BS, et al: Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98:6917–6922, 2001
[PubMed]
 
Elvevag B, Goldberg TE, Brown GDA, et al: Identification of tone duration, line length, and letter position: an experimental approach to timing and working memory deficits in schizophrenia. J Abnorm Psychol 113:509–521, 2004
[PubMed]
 
Farde L, Nordstrom AL, Wiesel FA, et al: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544, 1992
[PubMed]
 
Fitzgerald D, Lucas S, Redoblado MA, et al: Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics. Aust N Z J Psychiatry 38:501–510, 2004
[PubMed]
 
Flashman LA, Green MF: Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr Clin North Am 27:1–18, vii, 2004
 
Friedman JI: Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174:45–53, 2004
[PubMed]
 
Frith C: Functional imaging and cognitive abnormalities (review). Lancet 346:615–620, 1995
[PubMed]
 
Gao XM, Sakai K, Roberts RC, et al: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157:1141–1149, 2000
[PubMed]
 
Geyer MA, Heinssen R: New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr Bull 31:806–809, 2005
[PubMed]
 
Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774–1782, 2001
[PubMed]
 
Glynn SM, Marder SR, Liberman RP, et al: Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 159:829–837, 2002
[PubMed]
 
Gold JM, Goldberg RW, McNary SW, et al: Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395–1402, 2002
[PubMed]
 
Goldberg TE, Weinberger DR: Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 57:62–65, 1996
[PubMed]
 
Goldman-Rakic PS, Castner SA, Svensson TH, et al: Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174:3–16, 2004
[PubMed]
 
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330, 1996
[PubMed]
 
Gur RC, Ragland JD, Moberg PJ, et al: Computerized neurocognitive scanning, II: the profile of schizophrenia. Neuropsychopharmacology 25:777–788, 2001
[PubMed]
 
Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426–445, 1998
[PubMed]
 
Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975–981, 2000
[PubMed]
 
Hill SK, Ragland JD, Gur RC, et al: Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes. J Clin Exp Neuropsychol 24:765–780, 2002
[PubMed]
 
Hill SK, Beers SR, Kmiec JA, et al: Impairment of verbal memory and learning in antipsychotic-naive patients with first-episode schizophrenia. Schizophr Res 68:127–136, 2004
[PubMed]
 
Hoff AL, Svetina C, Maurizio AM, et al: Familial cognitive deficits in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 133B:43–49, 2005
 
Holcomb HH, Cascella NG, Thaker GK, et al: Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 153:41–49, 1996
[PubMed]
 
Kane JM, Woerner M, Weinhold P, et al: Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 20:39–40, 1984
[PubMed]
 
Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796, 1988
[PubMed]
 
Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286–293, 1999
[PubMed]
 
Karlsson P, Farde L, Halldin C, et al: PET study of D(1) dopamine receptor binding in neuroleptic-naïve patients with schizophrenia. Am J Psychiatry 159:761–767, 2002
[PubMed]
 
Kern RS, Green MF, Goldstein MJ: Modification of performance on the span of apprehension, a putative marker of vulnerability to schizophrenia. J Abnorm Psychol 104:385–389, 1995
[PubMed]
 
Kern RS, Green MF, Nuechterlein KH, et al: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res 72:11–19, 2004
[PubMed]
 
Kravariti E, Morris RG, Rabe-Hesketh S, et al: The Maudsley Early Onset Schizophrenia Study: cognitive function in adolescent-onset schizophrenia. Schizophr Res 65:95–103, 2003
[PubMed]
 
Kremen WS, Seidman LJ, Faraone SV, et al: Heterogeneity of schizophrenia: a study of individual neuropsychological profiles. Schizophr Res 71:307–321, 2004
[PubMed]
 
Krystal JH, Karper LP, Seibyl JP, et al: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214, 1994
[PubMed]
 
Lahti AC, Holcomb HH, Weiler MA, et al: Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry 53:601–608, 2003
[PubMed]
 
Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193–217, 2004
[PubMed]
 
Lewis DA, Volk DW, Hashimoto T: Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 174:143–150, 2004
[PubMed]
 
Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). N Engl J Med 353:1209–1223, 2005
[PubMed]
 
Love RC, Conley RR, Kelly DL, et al: A dose-outcome analysis of risperidone. J Clin Psychiatry 60:771–775, 1999
[PubMed]
 
Manoach D: Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 60:285–298, 2003
[PubMed]
 
Marder SR: The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci 8:109–113, 2006
[PubMed]
 
Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835, 1994
[PubMed]
 
Martin LF, Kem WR, Freedman R: Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174:54–64, 2004
[PubMed]
 
Medalia A, Revheim N: Computer assisted learning in psychiatric rehabilitation. Psychiatric Rehabilitation 3:77–98, 2004
 
Moghaddam B: Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39–44, 2004
[PubMed]
 
Mueser KT, Blanchard JJ, Bellack AS: Memory and social skill in schizophrenia: the role of gender. Psychiatry Res 57:141–153, 1995
[PubMed]
 
Myles-Worsley M, Park S: Spatial working memory deficits in schizophrenia patients and their first degree relatives from Palau, Micronesia. Am J Med Genet Neuropsychiatr Genet 114:609–615, 2002
[PubMed]
 
Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1–93, 2005
[PubMed]
 
Nisbet H, Siegert R, Hunt M, et al: Improving schizophrenic inpatients' Wisconsin card-sorting performance. Br J Clin Psychol 35:631–633, 1996
[PubMed]
 
Nuechterlein K, Barch D, Gold J, et al: Identification of separate cognitive factors in schizophrenia. Schizophr Res 72:29–39, 2004
[PubMed]
 
O'Carroll RE, Russell HH, Lawrie SM, et al: Errorless learning and the cognitive rehabilitation of memory-impaired schizophrenic patients. Psychol Med 29:105–112, 1999
[PubMed]
 
Okubo Y, Suhara T, Suzuki K, et al: Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634–636, 1997
[PubMed]
 
Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767–770, 1999
[PubMed]
 
Penades R, Boget T, Lomena F, et al: Brain perfusion and neuropsychological changes in schizophrenic patients after cognitive rehabilitation. Psychiatry Res 98:127–132, 2000
[PubMed]
 
Potkin SG, Saha A, Kujawa MJ, et al: Aripiprazole, an antipsychotic with a novel mechanism of action and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690, 2003
[PubMed]
 
Roth BL, Hanizavareh SM, Blum AE: Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24, 2004
[PubMed]
 
Saykin AJ, Gur RC, Gur RE, et al: Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48:618–624, 1991
[PubMed]
 
Saykin AJ, Shtasel DL, Gur RE, et al: Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124–131, 1994
[PubMed]
 
Seeger TF, Seymour PA, Schmidt AW, et al: Ziprasidone (CP-88, 059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101–113, 1995
[PubMed]
 
Seeman P: Dopamine receptors and psychosis. Science and Medicine 2(5):28–37, 1995
 
Selemon LD, Rajkowska G, Goldman-Rakic PS: Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 52:805–818, 1995
[PubMed]
 
Sharma RP, Shapiro LE: The 5-HT1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr Ann 26:88–92, 1996
 
Silverstein SM, Menditto AA, Stuve P: Shaping attention span: an operant conditioning procedure to improve neurocognition and functioning in schizophrenia. Schizophr Bull 27:247–257, 2001
[PubMed]
 
Silverstone T, Smith G, Goodall E: Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153:214–217, 1988
[PubMed]
 
Tamminga C: Glutamatergic aspects of schizophrenia. Br J Psychiatry Suppl 12–15, 1999
 
Tamminga CA, Kane JM: Olanzapine (Zyprexa): characteristics of a new antipsychotic. Expert Opin Investig Drugs 6:1743–1752, 1997
[PubMed]
 
Tollefson GD, Beasley CM Jr, Tran PV, et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457–465, 1997a
 
Tollefson GD, Tran PV, Hamilton S, et al: Olanzapine versus risperidone in the treatment of psychosis (abstract from The VIth International Congress on Schizophrenia Research. Colorado Springs, CO, April 12–16, 1997). Schizophr Res 24:191–192, 1997b
 
Tsai G, Passani LA, Slusher BS, et al: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829–836, 1995
[PubMed]
 
Twamley EW, Jeste DV, Lehman AF: Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. J Nerv Ment Dis 191:515–523, 2003
[PubMed]
 
Velligan DI, Bow-Thomas CC, Huntzinger C, et al: Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 157:1317–1328, 2000
[PubMed]
 
Vollema MG, Geurtsen GJ, van Voorst AJ: Durable improvements in Wisconsin Card Sorting Test performance in schizophrenic patients. Schizophr Res 16:209–215, 1995
[PubMed]
 
Weinberger DR, Berman KF, Suddath R, et al: Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149:890–897, 1992
[PubMed]
 
Weiner DM, Meltzer HY, Veinbergs I, et al: The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207–216, 2004
[PubMed]
 
Wexler BE, Hawkins KA, Rounsaville B, et al: Normal neurocognitive performance after extended practice in patients with schizophrenia. Schizophr Res 26:173–180, 1997
[PubMed]
 
Wexler BE, Anderson M, Fulbright RK, et al: Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. Am J Psychiatry 157:1694–1697, 2000
[PubMed]
 
Wirshing DA, Wirshing WC, Kysar L, et al: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358–363, 1999
[PubMed]
 
Wykes T, van der Gaag M: Is it time to develop a new cognitive therapy for psychosis: cognitive remediation therapy (CRT)? Clin Psychol Rev 21:1227–1256, 2001
[PubMed]
 
Wykes T, Reeder C, Corner J, et al: The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 25:291–307, 1999
[PubMed]
 
Wykes T, Brammer M, Mellers J, et al: Effects on the brain of a psychological treatment. Cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br J Psychiatry 181:144–152, 2002
[PubMed]
 
Zimbroff DL, Kane JM, Tamminga CA, et al: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782–791, 1997
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 21.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation